Anna V Durbin, 471320 Lowman St, Baltimore, MD 21230

7192593, Mar 20, 2007

Dec 8, 2000

09/733692

Brian R. Murphy - Bethesda MD, US
Peter L. Collins - Silver Spring MD, US
Alexander C. Schmidt - Washington DC, US
Anna P. Durbin - Takoma Park MD, US
Mario H. Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US

The United States of America, Represented by the Secretary, Department of Health and Human Services - Washington DC

A61K 39/12
A61K 39/155

4241991, 4242111, 435 691, 536 2372

Chimeric parainfluenza viruses (PIVs) incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric Ply genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.

7208161, Apr 24, 2007

May 22, 1998

09/083793

Brian R. Murphy - Bethesda MD, US
Peter L. Collins - Rockville MD, US
Anna P. Durbin - Germantown MD, US
Mario H. Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US

The United States of America, represented by the Secretary, Department of Health and Human Services - Washington DC

A61K 39/155
C12N 7/00

4242111, 4241991, 4352351, 435325, 4353201, 536 2372

Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.

7314631, Jan 1, 2008

Dec 10, 1999

09/458813

Brian R. Murphy - Bethesda MD, US
Peter L. Collins - Rockville MD, US
Anna P. Durbin - Takoma Park MD, US
Mario H. Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K 39/155
C12N 7/00

4242111, 4241991, 4352351, 435325, 4353201, 536 2372

Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.

7632508, Dec 15, 2009

Jan 4, 2006

11/324284

Alexander C. Schmidt - Washington DC, US
Mario H. Skiadopoulos - Potomac MD, US
Peter L. Collins - Rockville MD, US
Brian R. Murphy - Bethesda MD, US
Jane E. Bailly - Quebec, CA
Anna P. Durbin - Takoma Park MD, US

The United States of America - Washington DC

A61K 39/12
A61K 39/155

4241991, 4242111

Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different pathogen, including different PIV virus to form the human-bovine chimeric PIV genome or antigenome.

2005028, Dec 29, 2005

Aug 11, 2004

10/916827

Brian Murphy - Bethesda MD, US
Peter Collins - Rockville MD, US
Anna Durbin - Takoma Park MD, US
Mario Skiadopoulos - Potomac MD, US

C12Q001/70
C12Q001/68
G01N033/53
A61K039/12
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

435006000, 435007100, 435320100

Attenuated, recombinant negative stranded RNA viruses suitable for vaccine use are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the subject virus is modified to encode a mutation within a recombinant protein of the virus at one or more amino acid positions(s) corresponding to a site of an attenuating mutation in a heretologous, mutant negative stranded RNA virus. A similar attenuating mutation as identified in the heterologous negative stranded RNA virus is thus incorporated at a corresponding site within the recombinant virus to confer an attenuated phenotype on the recombinant virus. The attenuating mutation incorporated in the recombinant virus may be identical or conservative in relation to the attenuating mutation identified in the heterologous, mutant virus. By the transfer of mutations into recombinant negative stranded RNA viruses in this matter, candidate vaccine viruses are engineered to elicit a desired immune response against a subject virus in a host susceptible to infection thereby.

2008009, Apr 24, 2008

Apr 17, 2007

11/785364

Brian Murphy - Bethesda MD, US
Peter Collins - Bethesda MD, US
Anna Durbin - Takoma Park MD, US
Mario Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US
Alexander Schmidt - Bethesda MD, US
Jane Bailly - Sunnyvale CA, US

The Government of the US, Represented by the Secretary, Dept. of Health & Human Services - Rockville MD

C12N 7/00
C07H 21/04

435235100, 536023720

The invention provides isolated nucleic acids encoding recombinant genomes or antigenomes of Human Parainfluenza Viruses that are useful as vaccines. The recombinant genomes or antigenomes can be incorporated into expression vectors for production of recombinant viruses in vitro. The invention also provides recombinant Human Parainfluenza viruses having one or more mutations that attenuate replication of the virus in a host.

2009008, Mar 26, 2009

Jun 10, 2008

12/136765

Brian R. Murphy - Bethesda MD, US
Peter L. Collins - Rockville MD, US
Anna P. Durbin - Takoma Park MD, US
Mario H. Skiadopoulos - Potomac MD, US

C12P 21/00
C12N 7/01
C12N 15/44
C12N 15/63

435 691, 4352351, 536 2372, 4353201

Attenuated, recombinant negative stranded RNA viruses suitable for vaccine use are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the subject virus is modified to encode a mutation within a recombinant protein of the virus at one or more amino acid positions(s) corresponding to a site of an attenuating mutation in a heretologous, mutant negative stranded RNA virus. A similar attenuating mutation as identified in the heterologous negative stranded RNA virus is thus incorporated at a corresponding site within the recombinant virus to confer an attenuated phenotype on the recombinant virus. The attenuating mutation incorporated in the recombinant virus may be identical or conservative in relation to the attenuating mutation identified in the heterologous, mutant virus. By the transfer of mutations into recombinant negative stranded RNA viruses in this matter, candidate vaccine viruses are engineered to elicit a desired immune response against a subject virus in a host susceptible to infection thereby.

6410023, Jun 25, 2002

Jul 9, 1999

09/350821

Anna P. Durbin - Takoma Park MD
Peter L. Collins - Rockville MD
Brian R. Murphy - Bethesda MD

United States of America - Washington DC

A61K 3912

4241861, 4241841, 4241851, 4241991, 4242111, 4242121, 435 691, 435440, 4352523, 4353201

Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle.